Alnylam Pharmaceuticals, Inc.

ALNY Healthcare Biotechnology

Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024.

Revenue
+16.7%
EPS
+747.6%
Free cash flow
−4.76%
Total debt
−2.66%

Quarter to September 2026, against a year earlier

156.28 0.38 −0.24%
Market cap
$21.0B
P/E
7.9×
Fwd P/E
13.5×
Dividend yield
—
F-score
6/9
Altman Z
7.30
Beneish M
−1.95
Dividend safety
n/a
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Piotroski F-Score
5 7 7 6

+8 more TTM periods

ROE
138.07% 96.55% 90.36% 73.28%
ROA
41.25% 15.30% 11.52% 6.82%
ROIC
59.37% 0.00% 0.00% 0.00%
Return on Tangible Assets
72.30% 21.16% 15.88% 10.13%
Average Days of Receivables
78.99 69.35 75.26 76.42
Free Cash Flow per Share
6.02 6.14 4.84 3.52
Free Cash Flow
806.31 819.87 643.34 465.38
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026